People · Operator
Named in public records as an officer, director or promoter · active 2021–2023 · Pharmaceuticals, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Antios Therapeutics Inc. | — | Pharmaceuticals | Series C | $126.4M | $1.7B | 2021 |
| TwinStrand Biosciences, Inc. | — | Biotech / Pharma | Series C | $85.0M | $132.2M | 2023 |
DAVID CANNER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DAVID CANNER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chad Waite | 1 | 11 |
| Steve Dow | 1 | 7 |
| Craig Gordon | 1 | 6 |
| Gregory Mayes | 1 | 5 |
| Soma Somasegar | 1 | 5 |
| NICOLE VITULLO | 1 | 4 |
| Jason Myers | 1 | 4 |
| Michael Pellini | 1 | 4 |
| Benjamin Rovinski | 1 | 3 |
| Mike Pellini | 1 | 3 |
| Christopher Benoit | 1 | 3 |
| Iyona Rajkomar | 1 | 3 |
| Jesse Salk | 1 | 3 |
| Idean Marvasty | 1 | 2 |
| Scott Morenstein | 1 | 2 |
| Michael Kranda | 1 | 2 |
| Linden Rhoads | 1 | 2 |
| Ronnie Andrews | 1 | 2 |
| Chris Igielski | 1 | 2 |
| Patrick Higgins | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.